Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

SII B.1.617.2

Vaccine (Recombinant protein vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by Novavax

Phase 1/2 Most advanced trial (none active)

NVAX Developer

1 Registered trials

What is SII B.1.617.2?

SII B.1.617.2 is a monovalent protein subunit vaccine against the SARS-CoV-2 Delta variant, formulated with Matrix-M1 adjuvant. It is administered as intramuscular injections in doses ranging from 3 to 10 μg, given as one or two doses. The vaccine is studied for COVID-19 prevention.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Recombinant protein vaccine)
Targets: SARS-CoV-2 spike protein (antigen)
Mechanism: Immune activation, directed at SARS-CoV-2 spike protein
Pathways: immune_activation
Therapy area: Infectious disease
Developer: Novavax (NVAX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05029856	Phase 1/2	Covid19	Withdrawn	NVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19

More from Novavax

CIC Vaccine Phase 3 EBOV GP Vaccine Phase 1 Fluzone HD Phase 2/3 ICC Vaccine Phase 1/2 NanoFlu Phase 3 NVX-CoV2372 Phase 2 NVX-CoV2373 Phase 3 NVX-CoV2515 Phase 3 NVX-CoV2540 Phase 3 NVX-CoV2601 Phase 2/3 NVX-CoV2705 Phase 3 qNIV Vaccine Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the NVAX page.

Follow NVAX, the company behind SII B.1.617.2

See NVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVAX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z